Developer docs
API playgroundTry for free, no card

Search company profiles

Response Biomedical

Full company profile

uuid0034tvq

Namestring
Response Biomedical
Legal namestring
Response Biomedical Corp.
Websiteurl
responsebio.com
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Response Biomedical Corp. is a privately held Canadian in-vitro diagnostics company founded in 1992 and headquartered in Vancouver, British Columbia. The company develops, manufactures, and commercializes rapid point-of-care diagnostic tests built around its proprietary RAMP (Rapid Analyte Measurement Platform) — a quantitative, self-calibrating immunoassay system that delivers lab-quality results in approximately 15 minutes directly from whole-blood samples without centrifugation. Its product portfolio spans five therapeutic categories: cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19 antigen), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika, CDC-validated). The core RAMP 200 instrument is a modular analyzer supporting 2, 4, or 6 simultaneous tests, with LIS connectivity, built-in QC, and a RAMP Portal for data management.

The company's go-to-market is primarily indirect, relying on a global network of channel partners led by a dedicated VP of Global Channel Strategy. End customers include acute care hospitals, emergency departments, clinical laboratories, public-health and vector-control programs, and women's health clinics. Pricing is quote-based with multi-year contracts. Response Biomedical holds ISO 13485:2016 and MDSAP certifications and has secured Health Canada approval for its COVID-19 antigen test. Recent strategic activity includes a March 2026 collaboration with Korea's Sugentech (KOSDAQ: 253840) and the June 2026 launch of the RAMP Xpress platform, which extends the franchise beyond acute care into chronic disease and wellness management.

Short descriptiontext

Response Biomedical develops and manufactures rapid point-of-care diagnostic tests built on its proprietary RAMP immunoassay platform, serving acute-care hospitals, clinical laboratories, and public-health programs through a global channel-partner network from its Vancouver, Canada base.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, in vitro diagnostics, cardiovascular testing, infectious disease testing, rapid diagnostic tests
Industry2 codes
PRIMARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Surgical & Medical Instruments & Apparatus3841
Product category
Point-of-Care In Vitro Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Test Kits and Platform Sales
TypeHardware Sales
Description

Response Biomedical generates revenue through the sale of its RAMP diagnostic test kits and RAMP 200 analyzers. The company offers tests across cardiovascular, sepsis, infectious disease, women's health, and arbovirus categories. Tests are sold to healthcare facilities, clinical laboratories, and vector control programs.

responsebio.com
2Channel Partner Sales
TypeHardware Sales
Description

Revenue generated through a network of channel partners who distribute RAMP products in their respective markets. Partners receive diagnostic tests and exceptional support levels.

responsebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Quote-based pricing for RAMP 200 analyzers and test cartridges
ModelOtherBilling cadenceMulti-year contract
Notes

Commercial pricing requires contacting the company directly through their website or sales team. The company offers demo and quote request options on their website.

responsebio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1RAMP
Description

The RAMP platform is a global leader in acute care diagnostic testing for triage directly from whole blood samples. It includes rapid, quantitative, self-calibrating analyzers like the RAMP 200.

responsebio.com
Core offering1 text field

Response Biomedical develops, manufactures, and markets the RAMP (Rapid Analyte Measurement Platform) line of rapid, quantitative, self-calibrating diagnostic tests and analyzers for point-of-care use. The company produces the RAMP 200 modular analyzer (configurable for 2, 4, or 6 parallel tests) plus a portfolio of immunoassay cartridges covering cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika) indications, designed to deliver lab-quality results from whole blood in approximately 15 minutes without centrifugation or maintenance contracts.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Lab-quality results in approximately 15 minutes
+4 more records
Product overview1 text field

Response Biomedical offers a platform-plus-tests architecture centered on the RAMP 200 rapid diagnostic system. The RAMP 200 is a self-calibrating, quantitative point-of-care platform that delivers lab-quality results in approximately 15 minutes from whole blood samples. This core platform runs a comprehensive portfolio of diagnostic tests organized across five therapeutic categories: Cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), Sepsis (Procalcitonin), Infectious Disease (Flu A+B, RSV, COVID-19), Women's Health (Total β-hCG), and Arbovirus testing. The company has recently expanded into chronic disease management with the launch of the RAMP Xpress platform. Accessories include barcode scanners and printers. All tests are designed for point-of-care use in acute care settings.

Product and service16 records
1RAMP 200 Analyzer
CategoryDiagnostic Analyzer Platform
Description

Rapid, quantitative, self-calibrating diagnostic analyzer providing lab-quality results from whole blood in approximately 15 minutes with modular 2/4/6 test ports, built-in QC, no maintenance, and LIS connectivity; designed for acute care hospitals, clinical labs, and point-of-care settings.

2RAMP Troponin I Test
CategoryCardiovascular Diagnostic Test
Description

Quantitative cardiovascular immunoassay cartridge for cardiac troponin I used to triage patients suspected of myocardial infarction in acute care settings.

3RAMP NT-proBNP Test
CategoryCardiovascular Diagnostic Test
Description

Quantitative cardiovascular immunoassay cartridge for N-terminal pro-B-type natriuretic peptide used in the evaluation of heart failure and cardiac function.

4RAMP D-Dimer Test
CategoryCardiovascular Diagnostic Test
Description

Quantitative coagulation immunoassay cartridge for D-dimer used in the diagnosis of deep vein thrombosis and pulmonary embolism.

5RAMP CK-MB Test
CategoryCardiovascular Diagnostic Test
Description

Quantitative cardiovascular immunoassay cartridge for creatine kinase-MB isoenzyme used as an adjunct test for cardiac injury assessment.

6RAMP Myoglobin Test
CategoryCardiovascular Diagnostic Test
Description

Quantitative cardiovascular immunoassay cartridge for myoglobin, an early marker of muscle damage including cardiac muscle injury.

7RAMP Procalcitonin Test
CategorySepsis Diagnostic Test
Description

Quantitative sepsis immunoassay cartridge for procalcitonin used for early sepsis diagnosis and monitoring in emergency and in-patient settings.

8RAMP Flu A+B Test
CategoryInfectious Disease Diagnostic Test
Description

Immunoassay cartridge for rapid detection of influenza A and B viruses, developed in collaboration with 3M.

9RAMP RSV Test
CategoryInfectious Disease Diagnostic Test
Description

Immunoassay cartridge for rapid detection of respiratory syncytial virus (RSV), co-developed with 3M.

10RAMP COVID-19 Antigen Test
CategoryInfectious Disease Diagnostic Test
Description

Immunoassay cartridge for rapid detection of SARS-CoV-2 antigen, authorized for professional use and at-home testing under Health Canada approval (November 2022).

11RAMP Total β-hCG Test
CategoryWomen's Health Diagnostic Test
Description

Quantitative immunoassay cartridge for total beta-human chorionic gonadotropin used in blood-based pregnancy testing for women's health and obstetrics settings.

12RAMP Arbovirus Tests
CategoryArbovirus Diagnostic Test
Description

Immunoassay cartridges for CDC-validated detection of mosquito-borne arboviruses including West Nile Virus, Dengue, and Zika, used by vector control and public health surveillance programs.

13RAMP Xpress Platform
CategoryDiagnostic Analyzer Platform
Description

New diagnostic platform launched by Response Biomedical that extends the RAMP architecture beyond acute care into chronic disease and wellness management markets.

14RAMP 200 Barcode Scanner
CategoryInstrument Accessory
Description

USB-connected, omni-directional, hands-free barcode scanner accessory for the RAMP 200 analyzer that scans operator and patient sample IDs.

15RAMP 200 Printer
CategoryInstrument Accessory
Description

Compact, portable thermal printer accessory for the RAMP 200 analyzer with easy-to-open paper system for printing test results.

16RAMP Portal
CategorySoftware Platform
Description

Customer-facing web portal for managing test results, data, and device connectivity for the RAMP diagnostic system.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Sugentech, Inc.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-24
Description

Response Biomedical announced a strategic collaboration with Sugentech, Inc. (KOSDAQ: 253840) on March 24, 2026, to support the advancement and commercialization of a next-generation testing platform in high-growth global markets. This partnership extends Response's global distribution capabilities.

responsebio.com
Strategic tierCoreTypeOthersAnnounced on2025-07-01
Description

Intertek provides ISO 13485:2016 and MDSAP certification services for Response Biomedical's Quality Management System, demonstrating regulatory compliance.

Strategic tierCoreTypeOthersAnnounced on2024-11-01
Description

Health Canada granted approval for the RAMP COVID-19 antigen test, enabling Response Biomedical to distribute the test in Canada.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Operates established POC blood-gas/electrolyte/metabolite and immunoassay analyzers (RAPIDPoint, epoc) across acute-care settings and competes with RAMP for hospital POC budget.

TypeDirect peer
Description

Develops and distributes IVD/POC test kits and platforms across cardiovascular, infectious disease, and other acute-care-adjacent indications, with both direct and channel sales.

TypeBroad incumbent
Description

Roche's cobas and CARDIAC POC line compete head-on with RAMP in acute-care cardiac markers like Troponin T and NT-proBNP, backed by Roche's global central-lab and POC infrastructure.

TypeDirect peer
Description

Hemochron and related specialty POC coagulation/IVD systems directly overlap with RAMP's D-Dimer and cardiac marker portfolio in the same acute-care sales motion.

TypeEmerging player
Description

POC viscoelastic hemostasis diagnostics (Quantra) for cardiac surgery and critical care — operates in a closely adjacent acute-care diagnostics niche targeted by Response's coagulation menu.

6Abbott (Point of Care / i-STAT)
TypeDirect peer
Description

Abbott's i-STAT system is the closest direct comparable — a handheld quantitative POC immunoassay platform delivering lab-quality results from whole blood in minutes for cardiac, sepsis, and coagulation markers, sold into the same acute-care hospital channels.

TypeDirect peer
Description

Nova's StatStrip and Prime Plus blood-gas/chemistry POC analyzers target the same hospital acute-care workflow, with overlapping product positioning around quantitative, lab-quality point-of-care results.

TypeDirect peer
Description

Specialist in coagulation/hemostasis diagnostics, including POC and specialty lab reagents, with product overlap to RAMP's D-Dimer and coagulation-focused cardiac markers.

9Boditech Med
TypeEmerging player
Description

Korean POCT specialist (ichroma II, AFIAS) selling quantitative POC immunoassays for cardiac, sepsis, and infectious markers — directly overlapping RAMP's application areas, primarily across APAC.

TypeBroad incumbent
Description

Broader IVD/POC player (Triage MeterPro, Sofia, QuickVue) competing in quantitative cardiac and infectious-disease POC, with much larger commercial scale and a direct-plus-channel sales model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Response Biomedical

Point-of-Care In Vitro Diagnosticsresponsebio.com

Response Biomedical develops and manufactures rapid point-of-care diagnostic tests built on its proprietary RAMP immunoassay platform, serving acute-care hospitals, clinical laboratories, and public-health programs through a global channel-partner network from its Vancouver, Canada base.

What Response Biomedical does

Response Biomedical Corp. is a privately held Canadian in-vitro diagnostics company founded in 1992 and headquartered in Vancouver, British Columbia. The company develops, manufactures, and commercializes rapid point-of-care diagnostic tests built around its proprietary RAMP (Rapid Analyte Measurement Platform) — a quantitative, self-calibrating immunoassay system that delivers lab-quality results in approximately 15 minutes directly from whole-blood samples without centrifugation. Its product portfolio spans five therapeutic categories: cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19 antigen), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika, CDC-validated). The core RAMP 200 instrument is a modular analyzer supporting 2, 4, or 6 simultaneous tests, with LIS connectivity, built-in QC, and a RAMP Portal for data management.

The company's go-to-market is primarily indirect, relying on a global network of channel partners led by a dedicated VP of Global Channel Strategy. End customers include acute care hospitals, emergency departments, clinical laboratories, public-health and vector-control programs, and women's health clinics. Pricing is quote-based with multi-year contracts. Response Biomedical holds ISO 13485:2016 and MDSAP certifications and has secured Health Canada approval for its COVID-19 antigen test. Recent strategic activity includes a March 2026 collaboration with Korea's Sugentech (KOSDAQ: 253840) and the June 2026 launch of the RAMP Xpress platform, which extends the franchise beyond acute care into chronic disease and wellness management.

Response Biomedical firmographics

Firmographics
Name
Response Biomedical
Legal name
Response Biomedical Corp.
Website
https://responsebio.com
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
51–100 employees
Short description
Response Biomedical develops and manufactures rapid point-of-care diagnostic tests built on its proprietary RAMP immunoassay platform, serving acute-care hospitals, clinical laboratories, and public-health programs through a global channel-partner network from its Vancouver, Canada base.
Ownership category
akta.pro rank

Response Biomedical industry classification

Industry
Product category
Point-of-Care In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAAAB
Hematology & Coagulation Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Point-of-care diagnostics
  • In vitro diagnostics
  • Cardiovascular testing
  • Infectious disease testing
  • Rapid diagnostic tests

Where Response Biomedical is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices2 records

Markets served

Response Biomedical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Diagnostic Test Kits and Platform Sales: Response Biomedical generates revenue through the sale of its RAMP diagnostic test kits and RAMP 200 analyzers. The company offers tests across cardiovascular, sepsis, infectious disease, women's health, and arbovirus categories. Tests are sold to healthcare facilities, clinical laboratories, and vector control programs.
  2. Channel Partner Sales: Revenue generated through a network of channel partners who distribute RAMP products in their respective markets. Partners receive diagnostic tests and exceptional support levels.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based pricing for RAMP 200 analyzers and test cartridges

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Response Biomedical product offering

Product offering

Core offering

Response Biomedical develops, manufactures, and markets the RAMP (Rapid Analyte Measurement Platform) line of rapid, quantitative, self-calibrating diagnostic tests and analyzers for point-of-care use. The company produces the RAMP 200 modular analyzer (configurable for 2, 4, or 6 parallel tests) plus a portfolio of immunoassay cartridges covering cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika) indications, designed to deliver lab-quality results from whole blood in approximately 15 minutes without centrifugation or maintenance contracts.

Product overview

Response Biomedical offers a platform-plus-tests architecture centered on the RAMP 200 rapid diagnostic system. The RAMP 200 is a self-calibrating, quantitative point-of-care platform that delivers lab-quality results in approximately 15 minutes from whole blood samples. This core platform runs a comprehensive portfolio of diagnostic tests organized across five therapeutic categories: Cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), Sepsis (Procalcitonin), Infectious Disease (Flu A+B, RSV, COVID-19), Women's Health (Total β-hCG), and Arbovirus testing. The company has recently expanded into chronic disease management with the launch of the RAMP Xpress platform. Accessories include barcode scanners and printers. All tests are designed for point-of-care use in acute care settings.

Differentiator

Problem solved

Functional benefit

Brands

  • RAMP: The RAMP platform is a global leader in acute care diagnostic testing for triage directly from whole blood samples. It includes rapid, quantitative, self-calibrating analyzers like the RAMP 200.

Products and services

  • RAMP 200 Analyzer Rapid, quantitative, self-calibrating diagnostic analyzer providing lab-quality results from whole blood in approximately 15 minutes with modular 2/4/6 test ports, built-in QC, no maintenance, and LIS connectivity; designed for acute care hospitals, clinical labs, and point-of-care settings.
  • RAMP Troponin I Test Quantitative cardiovascular immunoassay cartridge for cardiac troponin I used to triage patients suspected of myocardial infarction in acute care settings.
  • RAMP NT-proBNP Test Quantitative cardiovascular immunoassay cartridge for N-terminal pro-B-type natriuretic peptide used in the evaluation of heart failure and cardiac function.
  • RAMP D-Dimer Test Quantitative coagulation immunoassay cartridge for D-dimer used in the diagnosis of deep vein thrombosis and pulmonary embolism.
  • RAMP CK-MB Test Quantitative cardiovascular immunoassay cartridge for creatine kinase-MB isoenzyme used as an adjunct test for cardiac injury assessment.
  • RAMP Myoglobin Test Quantitative cardiovascular immunoassay cartridge for myoglobin, an early marker of muscle damage including cardiac muscle injury.
  • RAMP Procalcitonin Test Quantitative sepsis immunoassay cartridge for procalcitonin used for early sepsis diagnosis and monitoring in emergency and in-patient settings.
  • RAMP Flu A+B Test Immunoassay cartridge for rapid detection of influenza A and B viruses, developed in collaboration with 3M.
  • RAMP RSV Test Immunoassay cartridge for rapid detection of respiratory syncytial virus (RSV), co-developed with 3M.
  • RAMP COVID-19 Antigen Test Immunoassay cartridge for rapid detection of SARS-CoV-2 antigen, authorized for professional use and at-home testing under Health Canada approval (November 2022).
  • RAMP Total β-hCG Test Quantitative immunoassay cartridge for total beta-human chorionic gonadotropin used in blood-based pregnancy testing for women's health and obstetrics settings.
  • RAMP Arbovirus Tests Immunoassay cartridges for CDC-validated detection of mosquito-borne arboviruses including West Nile Virus, Dengue, and Zika, used by vector control and public health surveillance programs.
  • RAMP Xpress Platform New diagnostic platform launched by Response Biomedical that extends the RAMP architecture beyond acute care into chronic disease and wellness management markets.
  • RAMP 200 Barcode Scanner USB-connected, omni-directional, hands-free barcode scanner accessory for the RAMP 200 analyzer that scans operator and patient sample IDs.
  • RAMP 200 Printer Compact, portable thermal printer accessory for the RAMP 200 analyzer with easy-to-open paper system for printing test results.
  • RAMP Portal Customer-facing web portal for managing test results, data, and device connectivity for the RAMP diagnostic system.

Quantifiable outcome

  • Lab-quality results in approximately 15 minutes
  • +4 more outcomes

Companies that use Response Biomedical

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Response Biomedical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Response Biomedical partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Sugentech, Inc.coreStrategic or Co-development Partner · 24 March 2026Response Biomedical announced a strategic collaboration with Sugentech, Inc. (KOSDAQ: 253840) on March 24, 2026, to support the advancement and commercialization of a next-generation testing platform in high-growth global markets. This partnership extends Response's global distribution capabilities.
  • IntertekcoreOthers · 1 July 2025Intertek provides ISO 13485:2016 and MDSAP certification services for Response Biomedical's Quality Management System, demonstrating regulatory compliance.
  • Health CanadacoreOthers · 1 November 2024Health Canada granted approval for the RAMP COVID-19 antigen test, enabling Response Biomedical to distribute the test in Canada.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Response Biomedical competitors and assessment

Company assessment

Broad incumbents

  • Siemens Healthineers: Operates established POC blood-gas/electrolyte/metabolite and immunoassay analyzers (RAPIDPoint, epoc) across acute-care settings and competes with RAMP for hospital POC budget.
  • Roche Diagnostics: Roche's cobas and CARDIAC POC line compete head-on with RAMP in acute-care cardiac markers like Troponin T and NT-proBNP, backed by Roche's global central-lab and POC infrastructure.
  • QuidelOrtho: Broader IVD/POC player (Triage MeterPro, Sofia, QuickVue) competing in quantitative cardiac and infectious-disease POC, with much larger commercial scale and a direct-plus-channel sales model.

Direct peers

  • Sekisui Diagnostics: Develops and distributes IVD/POC test kits and platforms across cardiovascular, infectious disease, and other acute-care-adjacent indications, with both direct and channel sales.
  • Werfen (Instrumentation Laboratory): Hemochron and related specialty POC coagulation/IVD systems directly overlap with RAMP's D-Dimer and cardiac marker portfolio in the same acute-care sales motion.
  • Abbott (Point of Care / i-STAT): Abbott's i-STAT system is the closest direct comparable — a handheld quantitative POC immunoassay platform delivering lab-quality results from whole blood in minutes for cardiac, sepsis, and coagulation markers, sold into the same acute-care hospital channels.
  • Nova Biomedical: Nova's StatStrip and Prime Plus blood-gas/chemistry POC analyzers target the same hospital acute-care workflow, with overlapping product positioning around quantitative, lab-quality point-of-care results.
  • Helena Laboratories: Specialist in coagulation/hemostasis diagnostics, including POC and specialty lab reagents, with product overlap to RAMP's D-Dimer and coagulation-focused cardiac markers.

Emerging players

  • HemoSonics: POC viscoelastic hemostasis diagnostics (Quantra) for cardiac surgery and critical care — operates in a closely adjacent acute-care diagnostics niche targeted by Response's coagulation menu.
  • Boditech Med: Korean POCT specialist (ichroma II, AFIAS) selling quantitative POC immunoassays for cardiac, sepsis, and infectious markers — directly overlapping RAMP's application areas, primarily across APAC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Response Biomedical social profiles

Digital presence

Response Biomedical compliance and trust

Trust signal

Compliance2 records

Response Biomedical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Response Biomedical leadership team

Management profile

Number of profiles

Profiles3 records

Response Biomedical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Response Biomedical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Response Biomedical

What does Response Biomedical do?

Response Biomedical develops, manufactures, and markets the RAMP (Rapid Analyte Measurement Platform) line of rapid, quantitative, self-calibrating diagnostic tests and analyzers for point-of-care use. The company produces the RAMP 200 modular analyzer (configurable for 2, 4, or 6 parallel tests) plus a portfolio of immunoassay cartridges covering cardiovascular (Troponin I, NT-proBNP, D-Dimer, CK-MB, Myoglobin), sepsis (Procalcitonin), infectious disease (Flu A+B, RSV, COVID-19), women's health (Total β-hCG), and arbovirus (West Nile, Dengue, Zika) indications, designed to deliver lab-quality results from whole blood in approximately 15 minutes without centrifugation or maintenance contracts.

Is Response Biomedical a public or private company?

Response Biomedical is a private company. It is classified as unknown and is currently operating.

When was Response Biomedical founded?

Response Biomedical was founded in 1992. It employs 51 to 100 people.

Where is Response Biomedical based?

Response Biomedical is headquartered in Vancouver, Canada, in the North America region.

How does Response Biomedical make money?

Two revenue lines are on record. Diagnostic Test Kits and Platform Sales are the primary driver. The others are channel Partner Sales.

Who are Response Biomedical's main competitors?

Broad incumbents on record are Siemens Healthineers, Roche Diagnostics and QuidelOrtho. Direct peers are Sekisui Diagnostics, Werfen (Instrumentation Laboratory), Abbott (Point of Care / i-STAT), Nova Biomedical and Helena Laboratories. Emerging players are HemoSonics and Boditech Med.

Does Response Biomedical have an API?

No public API is recorded for Response Biomedical.

What industry is Response Biomedical in?

Response Biomedical's product category is Point-of-Care In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAB, Hematology & Coagulation Diagnostics, with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireResponse Biomedical Expands Global Diagnostics Portfolio with the Launch of the RAMP XpressResponse Biomedical launched the RAMP Xpress diagnostic platform for metabolic and inflammatory biomarker testing, with Health Canada Class II licenses and four cleared tests. The platform offers four assays including HbA1c, CRP, hsCRP, and microalbumin, delivering results in as little as 3 minutes. The company plans to develop at least four new assays later this year.openPR.comGlobal Troponin Market Is Booming Worldwide | Beckman Coulter, Response Biomedical, VitroThe global troponin market is projected to grow at a 12.5% CAGR from 2025 to 2032. Key players include Roche Diagnostics, Abbott Laboratories, Beckman Coulter, and others, with segmentation by product type, application, and end user. The report also covers regional outlook and competitive landscape.PrwebQuidel and Abbott Lead in Market for POC Cardiac Markers: Kalorama ReportKalorama Information's report ranks Quidel as the market leader in point-of-care cardiac markers, with Abbott, Roche, Siemens Healthineers, and Response Biomedical also among top companies. Quidel acquired Triage assets from Alere in 2017, and the report notes POC testing is expanding into new categories and venues.GlobeNewswireResponse Biomedical Corp. Completes Going-Private TransactionResponse Biomedical Corp. completed its going-private transaction, with shareholders receiving $1.12 per share or new shares. The company will become a wholly-owned subsidiary of 1077801 B.C. Ltd., and the TSX delisting is expected on December 2, 2016.GlobeNewswireResponse Biomedical Corp. Announces Third Quarter 2016 Financial Results and Update on Going-Private TransactionResponse Biomedical reported Q3 2016 revenue of $1.6M, down 55% year-over-year, with nine-month revenue of $5.1M. The company also received shareholder and court approval for its going-private arrangement with 1077801 B.C. Ltd., subject to Chinese regulatory approvals.GlobeNewswireResponse Biomedical Corp. Receives Court Approval of Going-Private TransactionResponse Biomedical Corp. received Supreme Court of British Columbia approval for its going-private transaction via a plan of arrangement. Completion is subject to Chinese government approvals and expected in Q4 2016. The TSX conditionally approved the deal.GlobeNewswireResponse Biomedical Corp. Receives Shareholder Approval of Going-Private TransactionResponse Biomedical Corp. received shareholder approval of its going-private transaction on September 16, 2016, with 99.98% of votes cast in favor. Shareholders will receive $1.12 per share, subject to TSX and court approval, with completion expected in the fourth quarter.GlobeNewswireResponse Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of ShareholdersResponse Biomedical reported Q2 2016 revenue of $1.3M, down 69% year-over-year, with a $2.6M first-half loss. The company filed a proxy for a special meeting to approve a $1.12-per-share acquisition by 1077801 B.C. Ltd., a joint venture of OrbiMed and Runda.GlobeNewswireResponse Biomedical Corp. Announces Closing of First Tranche of Private PlacementResponse Biomedical Corp. closed the first tranche of its non-brokered private placement, with OrbiMed Advisors acquiring 892,858 shares for approximately $500,000. The company expects the second tranche from Shanghai Runda to close subject to Chinese regulatory approvals. Proceeds will fund research, development, and working capital.BioSpaceResponse Biomedical Of Canada Acquired By OrbiMed And China IVD MakerResponse Biomedical, a Vancouver-Shanghai IVD company, will be taken private by OrbiMed funds and Shanghai Runda Medical Technology for $11 million, a 51% premium to yesterday's closing quote. Runda will expand Response's China presence while the company remains in Canada, and both will inject $1 million. OrbiMed Advisors already owns 50.1% of Response.